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Abstract 
Epigenetic profiling by chromatin immunoprecipitation followed by sequencing (ChIP-seq) has 
become a powerful tool for genome-wide identification of regulatory elements, for defining 
transcriptional regulatory networks and for screening for biomarkers. However, the ChIP-seq 
protocol for low-input samples is laborious, time-consuming and suffers from experimental 
variation, resulting in poor reproducibility and low throughput. Although prototypic microfluidic 
ChIP-seq platforms have been developed, these are poorly transferable as they require 
sophisticated custom-made equipment and in-depth microfluidic and ChIP expertise, while 
lacking parallelisation. To enable standardized, automated ChIP-seq profiling of low-input 
samples, we constructed microfluidic PDMS-based plates capable of performing 24 sensitive 
ChIP reactions within 30 minutes hands-on time and 4.5 hours machine-running time. These 
disposable plates can be conveniently loaded into a widely available controller for pneumatics 
and thermocycling. In light of the Plug and Play (PnP) ChIP plates and workflow, we named our 
procedure PnP-ChIP-seq. We demonstrate high-quality ChIP-seq on hundreds to few thousands 
of cells for all six post-translational histone modifications that are included in the International 
Human Epigenome Consortium set of reference epigenomes. PnP-ChIP-seq robustly detects 
epigenetic differences on promoters and enhancers between naïve and more primed mouse 
embryonic stem cells (mESCs). Furthermore, we used our platform to generate epigenetic 
profiles of rare subpopulations of mESCs that resemble the 2-cell stage of embryonic 
development. PnP-ChIP-seq allows non-expert labs worldwide to conveniently run robust, 
standardized ChIP-seq, while its high-throughput, consistency and sensitivity paves the way 




To allow proper organization and function, genomes contain regulatory layers of information 2 
generally referred to as the epigenome. The epigenome includes the binding of transcription 3 
factors (TF) and the presence of a wide range of chemical modifications that can be deposited on 4 
DNA and histones, such as methylation of DNA or acetylation on histone tails (Kouzarides 5 
2007). During embryonic and fetal development of mammalian organisms, establishment and 6 
maintenance of cellular identity is regulated through these modifications (Berger 2007). 7 
Furthermore, a myriad of diseases is caused or characterized by alteration of epigenetic patterns 8 
(Portela and Esteller 2010). Therefore, epigenetic changes represent a highly interesting layer of 9 
information for disease stratification and for personalized medicine (Heyn and Esteller 2012; 10 
Dirks et al. 2016). A plethora of studies have highlighted the role of various histone post-11 
translational modifications (hPTMs) in regulation of chromatin structure necessary for DNA 12 
accessibility during gene expression (Jenuwein and Allis 2001; Barski et al. 2007; Berger 2007; 13 
Kouzarides 2007; Dekker 2008). For example, the presence of trimethylation of lysine 4 on 14 
histone 3 (H3K4me3) at genomic loci is commonly associated with active promoters (Barski et 15 
al. 2007), while a combination of H3K27 acetylation (H3K27ac) and H3K4me1 is typical for 16 
active enhancers (Creyghton et al. 2010). H3K36me3 generally covers gene bodies of active 17 
genes (Barski et al. 2007). Conversely, the hPTMs H3K27me3 and H3K9me3 are associated 18 
with repressed genes and/or heterochromatin (Boyer et al. 2006; Barski et al. 2007; Martens et al. 19 
2010). As such, it has become clear that epigenetic profiling of hPTMs allows for the 20 
identification of regulatory elements in the genome. 21 
 22 
 3
During the last ten years, chromatin immunoprecipitation followed by sequencing (ChIP-seq) has 1 
become the method-of-choice for genome-wide profiling of TFs and hPTMs (Park 2009; 2 
Welboren et al. 2009; Collas 2010; Furey 2012). The ChIP-seq protocol relies on affinity 3 
purification of a DNA-binding protein by the use of antibodies. Characterization of the DNA 4 
associated with the protein of interest by high-throughput sequencing allows for identification of 5 
the protein binding sites at a genome-wide scale. However, the ChIP-seq workflow requires large 6 
amounts of material, is labor intensive and lacks robustness due to experimental variation (Ho et 7 
al. 2011; Chen et al. 2012; Landt et al. 2012). These drawbacks make the application of ChIP-seq 8 
challenging, in particular in settings where material is limited (Dirks et al. 2016). 9 
 10 
To facilitate ChIP-seq profiling of low-input samples, a range of strategies have been developed 11 
(O'Neill et al. 2006; Dahl and Collas 2007; Dahl and Collas 2008a; Dahl and Collas 2008b; Adli 12 
and Bernstein 2011; Brind'Amour et al. 2015; Rotem et al. 2015; Schmidl et al. 2015; Dahl et al. 13 
2016; van Galen et al. 2016; Weiner et al. 2016; Zhang et al. 2016; Skene et al. 2018; Ai et al. 14 
2019; Grosselin et al. 2019; Hainer et al. 2019; Kaya-Okur et al. 2019; Ku et al. 2019). Methods 15 
that have been applied include barcoding and pooling of multiple samples in the ChIP reaction 16 
(Rotem et al. 2015; van Galen et al. 2016; Weiner et al. 2016), small volume sonication (Adli 17 
and Bernstein 2011), substitution of sonication by a native MNase digestion approach 18 
(Brind'Amour et al. 2015), the use of carrier material (mainly used for ChIP-qPCR) (O'Neill et 19 
al. 2006) and application of a transposase for DNA cleavage and library generation (Schmidl et 20 
al. 2015; Ai et al. 2019; Kaya-Okur et al. 2019). Each of the various ChIP-seq methodologies 21 
yield incremental benefits, but suffer from (a combination of) low read complexity, lack of 22 
robustness, suboptimal throughput and lengthy and/or laborious protocols. On the other hand, 23 
 4
semi-automated workflows have been developed to increase reproducibility of ChIP-seq and 1 
reduce the workload of the laborious protocol (Aldridge et al. 2013; Berguet et al. 2014; Gasper 2 
et al. 2014; Wallerman et al. 2015), but these generally require high quantities of input material. 3 
Recent studies have shown the feasibility of combining low-input samples with automated 4 
workflows using microfluidic devices (Cao et al. 2015; Shen et al. 2015; Murphy et al. 2018). 5 
However, these prototypic platforms require dedicated, custom-made sophisticated laboratory 6 
equipment, have low throughput due to the limited number of samples that can be run in parallel 7 
(1 sample (Cao et al. 2015), 4 samples (Murphy et al. 2018) and 4 samples (Shen et al. 2015) in 8 
parallel, respectively) and are mainly focused on few or a single histone modification 9 
(H3K4me3). Therefore, despite showing proof-of-principle, further maturation of these platforms 10 
in terms of throughput, flexibility and standardization of the microfluidic platform is required to 11 
allow integration in workflows of major epigenetic profiling endeavors, such as the International 12 
Human Epigenome Consortium (IHEC), but also to allow implementation of these platforms in 13 
non-expert laboratories (Bujold et al. 2016; Fernandez et al. 2016; Stunnenberg et al. 2016). 14 
Similarly, throughput and standardization of ChIP-seq are key for implementation in clinical 15 
applications of epigenetic biomarkers. 16 
 17 
Here, we aimed to develop a fully automated, integrated and standardized Plug and Play (PnP) 18 
ChIP-seq microfluidic platform for low-input samples that can easily be implemented, which we 19 
call PnP-ChIP-seq. We set the following requirements to be fulfilled by PnP-ChIP-seq: (i) 20 
generation of high-quality data to enable genome-wide ChIP profiling of low-input biological 21 
samples; (ii) a standardized ChIP-seq procedure that is robust and is easy to implement in 22 
laboratories and facilities; (iii) compatibility with ChIP-seq profiling of the hPTMs H3K4me3, 23 
 5
H3K36me3, H3K27ac and H3K4me1, associated with gene activity, and H3K9me3 and 1 
H3K27me3, associated with repression of genes; together, this meets the IHEC requirements for 2 
generating reference epigenomes from biological samples (Bujold et al. 2016; Fernandez et al. 3 
2016; Stunnenberg et al. 2016); (iv) allowing high-throughput by processing a large number of 4 




Automated part of ChIP-seq in microfluidic ChIP workflows 3 
In recent years, a large range of low-input ChIP technologies have been pioneered (Supplemental 4 
Fig. S1). Although elegant, these approaches are generally very laborious and prone to multiple 5 
sources of noise due to the large number of handling steps. To increase precision, some low-6 
input workflows have been automated (Cao et al. 2015; Shen et al. 2015; Murphy et al. 2018), 7 
but these studies use custom-made devices requiring extensive microfluidics and/or ChIP-seq 8 
expertise (Supplemental Fig. S1). Therefore, we set out to develop an automated miniaturized 9 
low-input ChIP-seq workflow that can conveniently be adopted by users world-wide. As such, 10 
we developed our workflow on a widely available commercial controller for pneumatics and 11 
thermocycling, the Fluidigm C1tm Controller. We designed disposable polydimethyl siloxane 12 
(PDMS)-based integrated fluidic circuit (IFC) devices (Fig. 1), on which 24 parallel ChIPs are 13 
performed fully automated after loading into the controller. These newly-designed PDMS-based 14 
IFC devices for microfluidic ChIP are very different from the PDMS devices that have been 15 
developed for single cell captures and single cell RNA-seq workflows (Frederickson 2002; 16 
Durruthy-Durruthy and Ray 2018). 17 
 18 
The conventional ChIP workflow (Supplemental Fig. S2) starts with the collection of chromatin 19 
from cells, after which the chromatin is sheared either by enzymatic digestion (for example by 20 
the use of MNase) or by ultrasonication. In case of ultrasonication, the chromatin is usually 21 
crosslinked before harvesting to stabilize protein-protein and protein-DNA interactions. Next, the 22 
isolated chromatin fragments are probed for proteins of interest by antibodies. The antibodies 23 
 7
and associated chromatin fragments are captured, for example by a mix of Protein A and Protein 1 
G antibody binding beads (Prot A/G beads). After washings to remove non-specific fragments 2 
from the scaffold, the DNA fragments are eluted and sequenced to determine the binding sites of 3 
the protein of interest at a genome-wide scale. For the microfluidic workflow, we set out to 4 
automate the labor-intensive process of (i) coupling the antibody to the beads, (ii) binding of the 5 
chromatin to the antibodies, (iii) washing of the antibody-protein complexes that are bound to the 6 
beads to remove non-bound background and (iv) elution of the DNA (Fig. 1A; Supplemental Fig. 7 
S2). We designed the workflow such that the DNA that is harvested after our ChIP workflow (3 8 
µl in the standard protocol) can be directly used as input for DNA library construction required 9 
for sequencing, without the need to perform DNA purification. 10 
 11 
Microfluidic disposable plates used for miniaturized ChIP-seq 12 
For the development of the IFC devices used as hardware for our workflow, we designed PDMS 13 
valve-operated fluidic circuits produced using multi-layer soft-lithography (Unger et al. 2000) 14 
(Fig. 1B). The PDMS chip is mounted to a plastic carrier that forms the pneumatic and 15 
thermodynamic operation interface with the controller (the chip together with the plastic carrier 16 
will be called plate from here on) and contains 25 μl volume inlets and 4 larger reservoirs for 17 
reagent loading. The samples, beads, control line fluids as well as wash, harvesting and elution 18 
buffers can be conveniently loaded in the appropriate wells of the plate (Fig. 1B; Supplemental 19 
Fig. S3A). Each IFC plate consists of 24 parallel nanoliter-scale reactors that facilitate 20 
multiplexing of experiments, while in each reactor a single ChIP experiment is performed (Fig. 21 
1C; Supplemental Fig. S3B). The 24 reactors each have individual inputs for (i) antibody-22 
binding beads, and (ii) chromatin and antibody, the main reagents used for an 23 
 8
immunoprecipitation reaction. Each common wash and elution reagent is pre-filled into a single 1 
inlet of the microfluidic plate which serves all 24 reactors (Supplemental Fig. S3A). The plate 2 
facilitates loading of up to 4 of such buffers. To allow maximum flexibility, all control valves 3 
can be individually pressurized (Fig. 1C; red valves). 4 
At the start of the procedure, all reagents and the dissociated chromatin suspension are loaded 5 
into the inlets (Supplemental Fig. S3A), after which the entire circuitry is loaded onto the 6 
controller to start the ChIP protocol. All reagents are dead-end filled at the start of a microfluidic 7 
run in order to remove any bubbles present in the system while operating. We constructed the 8 
procedure such that a tightly packed column of micron-sized monodisperse antibody-binding 9 
beads is packed (Fig. 1A; loading through the green inlet and blue column) on which the 10 
immunoprecipitation is performed (Fig. 1D).  11 
 12 
This column is built upon a frit layer of inert beads, which are larger in size as compared to the 13 
beads used for the column (Fig. 1A; frit layer schematically represented in cyan at the bottom of 14 
the column) and function to prevent leaking of relatively small 2.8μm diameter beads through 15 
the 5μm-spaced drain at the bottom. The use of 30% glycerol solution as a carrier keeps the 16 
beads in suspension during the process of building the separation columns. After packing the 17 
beads, the column is washed using an equilibration buffer to remove any remaining glycerol 18 
(Fig. 1C; flowing through the pink channel). The chromatin sample, up to 8μl in volume, is 19 
flushed across the antibody binding column (Fig. 1C; flowing through the orange channel). The 20 
antibodies used can be loaded together with either the beads or with the chromatin. After binding 21 
of the specific chromatin fragments to the antibodies on the bead column, the column is washed 22 
using an equilibration buffer followed by a high salt wash buffer (Fig. 1C; flowing through the 23 
 9
pink channel). The specific DNA fragments associated with the protein of interest are eluted 1 
using a DNA extraction buffer incubated for 20 minutes at 55°C followed by an hour at 65°C 2 
(which decrosslinks when using fixed chromatin and degrades the Proteinase K; Fig. 1C; flowing 3 
through the pink channel). DNA elution buffer is used to push the eluted DNA fragments to the 4 
outlet wells to a final volume of 3µl. This DNA can directly be used for further processing (no 5 
clean-up step is needed) since the DNA extraction buffer containing the DNA fragments (~10nl) 6 
is highly diluted by the DNA elution buffer. During elution, the resulting DNA fragments are 7 
collected into individual outlets (Fig. 1C; via the yellow channel) and can be used for qPCR or 8 
sequencing. 9 
 10 
Optimization of microfluidic ChIP-qPCR 11 
For optimization of the microfluidic ChIP procedure, we tested a range of variables using ChIP-12 
qPCR on H3K4me3 in mouse embryonic stem cells (mESCs), using a well-known positive locus 13 
of a highly active gene (Actb) and a negative locus in a gene-desert for background control as 14 
read-out. H3K4me3 is mainly present at promoters of active genes (Barski et al. 2007). For 15 
testing, the main variables included (i) the composition of the frit layer, (ii) the size of the 16 
column used for immunoprecipitation, (iii) the type of beads, and (iv) the pressure used to load 17 
the sample on the columns (Fig. 2A-D). For these tests, we used a small quantity of bulk-isolated 18 
chromatin to load on each bead column: an amount of chromatin equivalent to 3,000 mESCs. We 19 
aimed as using small beads as it allows for a large surface area in the columns to capture 20 
chromatin fragments. As such, the small columns have an >100-fold excess of H3K4me3 21 
binding sites relative to the amount of H3K4me3 present in 3,000 mESCs, while for the large 22 
columns the H3K4me3 binding sites are >1,000 fold in excess. The results showed that a frit 23 
 10
layer composed of a mixture of 4.5µm and 6µm inert beads (Fig. 2A), combined with large 1 
columns (Fig. 2B; Supplemental Fig. S4A) composed of an equal mix of 2.8µm ProtA and ProtG 2 
beads (Fig. 2C) resulted in optimal recoveries. The pressure used to load the samples was less 3 
critical (Fig. 2D). Altogether, these tests resulted in a significant improvement of ChIP-qPCR 4 
recoveries as compared to an initial, default workflow that we applied (Fig. 2E). The hands-on 5 
time for the optimized microfluidic protocol is very limited, in total around 30 minutes 6 
(Supplemental Fig. S5A): preparation including pipetting of the plate takes at maximum 20 7 
minutes, while harvesting of the 24 DNA samples of the ChIP takes another 10 minutes of 8 
hands-on time. The hands-free multiplexed immunoprecipitation process that is performed on the 9 
bead columns takes approximately 4.5 hours (Supplemental Fig. S5). 10 
 11 
Microfluidic ChIP is sensitive and robust 12 
We next evaluated the performance of the optimized workflow over the 24 individual reactors of 13 
a microfluidic chip by routinely constructing 24 separate, parallel antibody affinity bead columns 14 
on each microfluidic chip (Supplemental Fig. S4B). For ChIP-qPCR, the results obtained for 15 
individual columns of a single microfluidic chip were highly consistent, with 40.1% +/- 0.15% 16 
recovery of H3K4me3 over the Actb promoter (Fig. 2F: columns named A-P). This shows that 17 
using the optimized workflow all individual columns are above a critical size resulting in optimal 18 
recoveries. The mock controls, in which no chromatin was present, did not show any recovery 19 
for either the positive or negative locus, indicating there was no cross-contamination during our 20 
procedures or on the PDMS chip (Fig. 2F: columns named Q-X). Furthermore, we observed very 21 
high consistency between ChIP-qPCRs performed on separate microfluidic plates (Supplemental 22 
Fig. S4C) run on different days. 23 
 11
To evaluate the results of the optimized microfluidic ChIP procedure, we compared our results to 1 
conventional ChIP-qPCRs using the equivalent of 500,000 or 10,000 mESCs from a bulk mESC 2 
sonicated sample as input. In line with the fact that lower input quantities affect the efficiency of 3 
ChIP (Kidder et al. 2011; Hainer et al. 2019; Ku et al. 2019), we observed a 5-fold reduction in 4 
recovery in conventional bench ChIP-qPCRs performed using 10,000 mESCs as compared to the 5 
ChIP-qPCRs performed using 500,000 mESCs (Fig. 2F, left part labeled 1-3). The relative 6 
recoveries obtained using the microfluidic ChIP-qPCR procedure using 3,000 mESCs (40.10% 7 
+/- 0.15%) were much higher as compared to conventional ChIP-qPCRs using chromatin of 8 
10,000 mESCs (7,44% +/- 0,60%) and also slightly higher than the recoveries obtained for 9 
conventional ChIP-qPCRs using chromatin of 500,000 mESCs (37.22% +/- 0.46%) (Fig. 2F). 10 
Along with greatly enhanced Actb recoveries for the optimized and automated low-cell ChIPs, 11 
we consistently observed a slightly increased recovery for the negative control in the 12 
microfluidic ChIP-qPCR as compared to conventional ChIP-qPCR (Fig. 2F). This might be 13 
caused by the fact that the antibody-beads are present in a column in our workflow, which does 14 
not allow to resuspend the beads during washing as in regular ChIP. Altogether, this shows that 15 
the miniaturized platform is superior over conventional low-input bench ChIP protocols and that 16 
the microfluidic platform efficiently generates highly reproducible ChIPs on very small 17 
quantities of cells. 18 
 19 
Microfluidic PnP-ChIP-seq for epigenetic profiles of histone modifications 20 
Next, we used our optimized automated ChIP workflow for ChIP-seq, a procedure which we 21 
named Plug and Play (PnP)-ChIP-seq (Supplemental Methods). To optimize the PnP-ChIP-seq, 22 
we used crosslinked and sonicated chromatin obtained from “bulk” (multi-million) mESC 23 
 12
chromatin preparations. We loaded the chromatin equivalent of 3,000, 1,000 and 500 mESCs on 1 
the microfluidic platform to generate H3K4me3 ChIP-seq profiles, with replicate experiments 2 
performed on separate microfluidic chips to probe for consistency between runs. Visual 3 
inspection shows a high overlap of enriched sites of the low-input PnP-ChIP-seq profiles as 4 
compared to the bulk reference track (Fig. 3A; Supplemental Fig. S6A), albeit at lower signal 5 
intensities. We next performed peak calling, and plotted the ChIP-seq signals over the merged 6 
peak set. These plots further confirmed the reduction in H3K4me3 signal intensities when using 7 
lower number of cells as input, as reflected in the heatmaps (Fig. 3B) and average plots 8 
(Supplemental Fig. S6B). However, the Pearson’s correlation of the intensities of the joint peaks 9 
between all different H3K4me3 profiles was very high (r > 0.87), both between bulk ChIP-seq 10 
and PnP-ChIP-seq as well as between profiles generated by PnP-ChIP-seq using different input 11 
quantities (Fig. 3C), confirming the high quality of profiles generated using the microfluidic 12 
platform. De novo peak calls on 3,000 cell microfluidic ChIP showed that we detected 85% of 13 
the bulk reference peak set (Fig. 3D), with hardly any peaks being detected outside the bulk 14 
reference peak set, while the profiles generated using the chromatin equivalent of 3,000 or 1,000 15 
mESCs show a high overlap (Fig. 3E). Furthermore, the ChIP-seq profiles generated using the 16 
microfluidic platform are highly reproducible, as shown by the Pearson’s correlations (Fig. 3C) 17 
and by the peak overlap of the replicate H3K4me3 profiles using the chromatin equivalent of 18 
3,000 mESCs (Fig. 3F). 19 
 20 
Besides H3K4me3, we set out to use our platform for profiling of the additional hPTMs 21 
H3K4me1 and H3K27ac, that together allow to define active and poised enhancers (Creyghton et 22 
al. 2010), and H3K36me3, which covers the gene body of active genes (Barski et al. 2007). For 23 
 13
the three additional hPTMs, we used the chromatin equivalent of 3,000 and 1,000 mESCs for 1 
PnP-ChIP-seq. Visual inspection of the profiles generated confirmed the anticipated location of 2 
enhancers and active gene bodies, respectively, and also showed the similarity between the bulk 3 
reference track and the PnP-ChIP-seq tracks (Fig. 3A; Supplemental Fig. S6A). Similar to 4 
H3K4me3, the H3K4me1 and H3K27ac profiles show a reduction in signal associated with the 5 
number of cells used as input for the PnP-ChIP-seq (Fig. 3B). Further analysis using 6 
correlograms showed the PnP-ChIP-seq tracks of H3K4me1, H3K27ac and H3K36me3 were 7 
well in concordance with ChIP-seq tracks using bulk material, albeit the Pearson’s correlations 8 
were somewhat lower as compared to the profiles generated for H3K4me3 (Fig. 3C). The 9 
majority of peaks called for H3K4me1, H3K27ac and H3K36me3 were also present in the bulk 10 
reference set, with between 65% and 76% of the bulk peaks being called (Fig. 3D). The use of 11 
1,000 mESCs resulted in a clear drop in signals: although for H3K27ac we were still able to call 12 
most of the peaks as present in the bulk reference set, this number dropped to 30% and 56% for 13 
H3K36me3 and H3K4me1, respectively (Fig. 3E). Altogether, these analyses show the 14 
compatibility of our microfluidic platform to comprehensively profile the main epigenetic hPTM 15 
marks associated with gene activity using very low sample quantities of 3,000 mESCs, while the 16 
use of even lower numbers of mESCs generally results in a reduction in sensitivity. 17 
 18 
PnP-ChIP-seq is compatible with low abundant populations of cells 19 
Having established the sensitivity of our platform on small quantities of chromatin prepared from 20 
bulk collections, we set out to make the microfluidic platform compatible with ChIP-seq 21 
profiling of low-abundant populations of cells that are not easily collected in large amounts. The 22 
preparation of chromatin from a low number of cells is challenging, in particular when using 23 
 14
sonication for chromatin shearing. We extensively tested sonication on low quantities of cells, 1 
but this resulted in a gradual loss of ChIP-seq signal when reducing the amount of input 2 
chromatin used for shearing (Supplemental Fig. S7A,B). Therefore, we switched to low-input 3 
MNase digestion for shearing of native (non-crosslinked) chromatin. We took a fixed number of 4 
7,500 or 15,000 mESCs for MNase digestions, and subsequently used the chromatin equivalent 5 
of 3,000, 1,000, 500 and 100 mESCs for H3K4me3 ChIP-seq as input for the microfluidic 6 
platform (Fig. 4A; Supplemental Fig. S8A). Visual inspection showed the H3K4me3 PnP-ChIP-7 
seq profiles were very similar to the bulk reference profiles generated by conventional ChIP-seq 8 
(using 2 million mESCs), independent of the number of mESCs loaded on the platform. Peak 9 
calling on the individual profiles showed a high overlap of peak calls between the bulk reference 10 
set and the H3K4me3 PnP-ChIP-seq profiles generated using the 3,000 mESC chromatin 11 
equivalent (Fig. 4B). The use of a smaller number of mESCs resulted in concentration-dependent 12 
decrease of H3K4me3 peaks and signals (Fig. 4B,C; Supplemental Fig. S8b), which is known for 13 
low-input ChIP-seq (Kidder et al. 2011; Hainer and Fazzio 2019; Ku et al. 2019). However, even 14 
with as few as 100 mESC chromatin equivalent we were still able to call 53% of the peaks as 15 
present in bulk H3K4me3 ChIP-seq (Fig. 4B). The results between the different starting 16 
amounts, 7,500 or 15,000 mESCs, were similar (Fig. 4A). Even with these low starting amounts, 17 
the H3K4me3 PnP-ChIP-seq profiles generated using the MNase-based protocol showed higher 18 
signal-to-noise ratios compared to the H3K4me3 PnP-ChIP-seq profiles generated using 19 
chromatin that was sonicated in bulk (Supplemental Fig. S8C). Quantification of the merged 20 
H3K4me3 peak set of the MNase-based profiles showed a very high correlation (Fig. 4D), with 21 
cross-correlations between low cell-input experiments and the bulk reference of r > 0.82 22 
(Pearson’s correlation) and high consistency between technical replicates separated before 23 
 15
MNase treatment (r > 0.88), Also, the majority of peaks were consistently detected in all 1 
technical replicates irrespective of the number of mESCs that was used as input for the PnP-2 
ChIP-seq (Supplemental Fig. S8D), further underlining the high quality of the ChIP-seq profiles 3 
generated by the microfluidic platform. To further evaluate the performance of the PnP-ChIP-4 
seq, we performed comparative analysis to other low-input ChIP-seq technologies that have been 5 
developed and have included H3K4me3 ChIP-seq on mESCs in their studies, in particular ChIP-6 
seq profiles of 1,000 mESCs on a previously developed prototype microfluidic platform (Shen et 7 
al. 2015) and low-input native ChIP-seq profiles generated using the ULI-NChIP-seq bench 8 
protocol (Brind'Amour et al. 2015). In terms of the number of peak calls, our microfluidic ChIP-9 
seq compared favorably with ULI-NChIP-seq, and is comparable to the prototypic microfluids 10 
platform (Supplemental Fig. S9A). However, in terms of signal-to-noise ratio (Supplemental Fig. 11 
S9b) and similarity to the bulk reference (Supplemental Fig. S9C), our PnP-ChIP-seq was shown 12 
to be superior to both methods that were previously developed. 13 
 14 
PnP-ChIP-seq is compatible with profiling of all six reference epigenomes 15 
In view of the high sensitivity of the MNase-based native PnP-ChIP-seq H3K4me3 profiles, we 16 
included H3K4me1, H3K27ac and H3K36me3 for further profiling of the mESCs, using the 17 
same protocol with a chromatin equivalent of 3,000 mESCs (obtained from a sample of 15,000 18 
mESCs). Visual inspection of the profiles generated using the microfluidic platform confirmed 19 
the anticipated location, and also showed the similarity between the bulk reference track and the 20 
PnP-ChIP-seq profiles (Fig. 4A; Supplemental Fig. S8A). Although the similarity to bulk ChIP-21 
seq for these hPTMs was somewhat lower as compared to H3K4me3, the Pearson’s correlation 22 
of r > 0.58 (Supplemental Fig. S10A), the heatmap over the peaks (Fig. 4C) and the overlap of 23 
 16
peaks as compared to bulk ChIP-seq (Supplemental Fig. S10B) showed that the PnP-ChIP-seq 1 
profiles were of very good quality. Although the signal intensities of H3K27ac of the 3,000 2 
mESCs were reduced as compared to the bulk (Fig. 4C), peak calling identified around half of 3 
the H3K27ac enriched sites (Supplemental Fig. S10B). Also, the 3,000 mESC profiles of 4 
H3K4me1, H3K27ac and H3K36me3 showed high reproducibility (Fig. 4C,D; Supplemental 5 
Fig. S10C). 6 
To explore the compatibility of our platform with hPTMs associated with gene silencing, we 7 
performed PnP-ChIP-seq for H3K27me3 and H3K9me3. H3K27me3 is typically present at silent 8 
genes, in particular for developmental genes in mESCs (Boyer et al. 2006). Accordingly, we 9 
observed strong enrichment of H3K27me3 by PnP-ChIP-seq for the developmental regulators 10 
Gata6 and Lhx1 and over the Hoxb cluster (Supplemental Fig. S11A), both for the sonication-11 
based and for the MNase based workflows that we developed. The average profile over the 12 
merged H3K27me3 peak set as detected in mESCs shows a clear enrichment for the PnP-ChIP-13 
seq profiles, similar to H3K27me3 generated by the low-input STAR ChIP-seq strategy (Zhang 14 
et al. 2016) (Supplemental Fig. S11B). In mESCs, H3K9me3 is mainly present over major 15 
satellite repeats, both at pericentric heterochromatin and intergenic, but also over various other 16 
type of repetitive regions such as LINEs/ERVs (Martens et al. 2005; Bulut-Karslioglu et al. 17 
2014). Using PnP-ChIP-seq, we observed a H3K9me3 pattern similar to H3K9me3 mESC bulk 18 
ChIP-seq profiling (Supplemental Fig. S11C). As expected, we observed a very high enrichment 19 
of major satellite sequences in the PnP-ChIP-seq, while it was depleted over repeats such as 20 
SINEB (Alu) that is located in gene-rich regions (Deininger 2011) and associated with hPTMs 21 
associated with gene activity (Supplemental Fig. S11D). In conclusion, these experiments show 22 
that by the use very small cell quantities, we were able to perform comprehensive epigenetic 23 
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profiling of all six hPTMs required by IHEC for generating reference epigenomes from 1 
biological samples (H3K4me3, H3K36me3, H3K27ac, H3K4me1, H3K9me3 and H3K27me3) 2 
using PnP-ChIP-seq in an automated fashion. 3 
 4 
PnP-ChIP-seq robustly detects epigenetic differences between two types of mESCs 5 
Having shown the compatibility of MNase PnP-Chip-Seq for multiple hPTMs, we next asked 6 
whether the workflow we developed would have enough sensitivity to detect differences between 7 
two cell populations. Therefore, we performed low-input MNase PnP-ChIP-seq for H3K4me3, 8 
H3K27ac and H3K4me1 on two types of mESCs: ground-state pluripotent ES cells grown under 9 
serum-free conditions using two kinase inhibitors (“2i”) (Ying et al. 2008) and metastable serum-10 
grown ES cells (“serum”), which contain features of primed pluripotency (Habibi et al. 2013). 11 
Despite the fact that these two cell types are relatively similar (Marks et al. 2012), PnP-ChIP-seq 12 
profiling readily picked up differences between these cell types. Using principal component 13 
analysis (PCA) on each of the three hPTMs that we profiled, the 2i mESC replicas clearly 14 
separated from the serum mESC replicas along the main principal component 1 (PC1), 15 
explaining 85-91% of the variation between the samples (Fig. 5A). For H3K4me3, we detected 16 
in total 25,617 H3K4me3 peaks, of which 3,459 peaks were significantly higher in either 2i 17 
mESCs or serum mESCs (Supplemental Fig. S12; Supplemental Table S1). These included 18 
differential peaks that are associated with well-known genes that are significantly higher 19 
expressed in 2i mESCs (Tex14 and Ubc) or serum mESCs (Lin28b, Dnmt3l and Cdk12; Fig. 5B; 20 
Supplemental Fig. S13). Similarly, we were able to call significant differences between 2i and 21 
serum mESCs for H3K27ac and H3K4me1 (Fig. 5B; Supplemental Fig. S12,S14,S15; 22 
Supplemental Table S1). Functional annotation clustering of differential H3K4me3 by Gene 23 
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Ontology (GO) and pathway analysis (Fig. 5C) revealed that genes associated with increased 1 
H3K4me3 in 2i are significantly enriched for terms associated with metabolic processes, cell 2 
cycle, early embryonic development and Wnt signaling. Genes associated with increased 3 
H3K4me3 in serum are significantly linked to the GO terms related to metabolic processes and 4 
post-implantation germ layer specification. As similar terms were identified using differential 5 
gene expression between 2i and serum mESCs (Marks et al. 2012; Marks and Stunnenberg 6 
2014), changes in H3K4me3 between 2i and serum mESCs are very well reflected in the 7 
transcription in these mESCs. Altogether, these experiments show that PnP-ChIP-seq robustly 8 
picks up relevant significant epigenetic differences between two closely related cell types. 9 
 10 
The H3K4me3 landscape of 2-cell stage like mESCs is similar regular mESCs 11 
mESC cultures are heterogeneous (Kolodziejczyk et al. 2015), and gene expression analysis 12 
showed that a small number of mESCs within the total mESC population represent the 2-cell 13 
stage of embryonic development (“2 cell-stage like” (2C-like) cells) (Morgani and Brickman 14 
2014; Fu et al. 2020). Previous research suggested that enhancers (as profiled by H3K27ac and 15 
H3K4me1 ChIP-seq) are similar between 2C-like cells and regular mESCs, while also 16 
differences in the localization of H3K27me3 are minimal (Hayashi et al. 2016; Zhang et al. 17 
2019). In line, we did not find significant differences between 2C-like cells and regular mESCs 18 
in the H3K27ac, H3K4me1 and H3K27me3 ChIP-seq profiles generated in these studies 19 
(Supplemental Fig. S17A). This might indicate that the 2C-like cells occur in the mESC cultures 20 
by stochastic changes in gene expression rather than by epigenetic changes. To discriminate 21 
between these two scenarios, we used PnP-ChIP-seq to profile H3K4me3, an epigenetic mark 22 
that has a very high correlation with gene expression (Barski et al. 2007). We performed 23 
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fluorescent-activated cell sorting (FACS) for distinct low-abundant subpopulations of mESCs, as 1 
previously reported, based on promoter activity of Hhex (Morgani et al. 2013; Morgani and 2 
Brickman 2014), Zscan4c (Falco et al. 2007; Macfarlan et al. 2012; Eckersley-Maslin et al. 2016; 3 
Ishiguro et al. 2017) and MuERV-L (MERVL) (Macfarlan et al. 2012; Eckersley-Maslin et al. 4 
2016). We made use of fluorescent reporters in three different mESC lines: (i) a Venus-positive 5 
subpopulation of mESCs sorted using a Hhex::Venus reporter, that has been shown to be 6 
totipotent-like (Morgani et al. 2013; Morgani and Brickman 2014); (ii) an Emerald-GFP-positive 7 
subpopulation of mESCs sorted using a Zscan4c::Emerald-GFP reporter, that has been reported 8 
to be 2C-like cells (Falco et al. 2007; Macfarlan et al. 2012; Eckersley-Maslin et al. 2016; 9 
Ishiguro et al. 2017); and (iii) a TdTomato-positive population of mESCs sorted using a 10 
MERVL::TdTomato reporter, which is a subselection of the ZSCAN4-positive mESC population 11 
(Macfarlan et al. 2012; Eckersley-Maslin et al. 2016) (Fig. 6A). The FACS profiles showed that 12 
we were able to collect discrete subpopulations of mESCs based on their fluorescent markers 13 
(Supplemental Fig. S16). We validated the sorting by comparing expression of the marker-14 
positive populations versus expression of the marker-negative populations using RT-qPCR. We 15 
detected increased RNA expression of the sorted subpopulation marker as well as the 16 
corresponding fluorescent transcript and multiple other specific markers for the subpopulations 17 
as reported in the original studies (Fig. 6B) (Morgani et al. 2013; Eckersley-Maslin et al. 2016), 18 
confirming that we obtained the anticipated subpopulations of 2C-like cells. Next, we used PnP-19 
ChIP-seq to profile H3K4me3 for the mESCs populations showing Hhex, Zscan4c and MERVL 20 
promoter activity by means of positive marker expression, as well as for the populations of 21 
mESCs that were negative for the markers (Fig. 6C,D). Visual inspection of the H3K4me3 22 
profiles showed that the Venus, Emerald-GFP and TdTomato-positive mESCs were similar to 23 
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their negative counterparts (Fig. 6C), including the H3K4me3 signals at the promoters of the 1 
core pluripotency factors Nanog, Oct4 and Sox2 (Fig. 6D). Next, we quantified genome-wide 2 
enrichment of H3K4me3 at 1kb regions around all promoters. Subsequent PCA showed that 3 
none of the main PCs consistently separated the 2C-like cells from the remainder of the mESCs 4 
(Fig. 6E). We observed a very high correlation in H3K4me3 intensities between the Venus, 5 
Emerald-GFP and TdTomato-positive mESC subpopulations as compared to their respective 6 
negative mESC subpopulations (Fig. 6F). Statistical analysis for differential H3K4me3 sites 7 
using DESeq2 (Love et al. 2014) showed that none of the H3K4me3 enriched loci in the three 8 
2C-like cell populations was significantly different from the remainder of the populations (Fig. 9 
6F), while also an overall comparison of three marker-negative versus three marker-positive cell 10 
populations did not yield any significant differences (FDR-adjusted p-value <0.05; Supplemental 11 
Table S2). Specifically focusing on genes that are changing in 2C-like cells as compared to 12 
regular mESCs (Fu et al. 2020), the group of upregulated genes in 2C-like cells did not show a 13 
significant difference in H3K4me3, while the group of downregulated genes show a small but 14 
significant decrease in H3K4me3 in the 2C-like cells for all three mESC lines (Supplemental 15 
Fig. S17B). Altogether, this shows that the transcriptional changes associated with the 2C-like 16 
state (Falco et al. 2007; Macfarlan et al. 2012; Morgani et al. 2013; Eckersley-Maslin et al. 2016) 17 
are largely uncoupled from the H3K4me3 epigenetic landscape. This suggests that propagation 18 
of the expanded potential of mESCs in the 2C-like or totipotent-like state might occur by a 19 
stochastic increase in transcriptional activity of genes associated with these states rather than by 20 
stable epigenetic (H3K4me3-associated) alterations.  21 
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Discussion 1 
Determining protein binding sites on DNA by means of ChIP-seq is key to our understanding of 2 
gene regulation (Jenuwein and Allis 2001; Barski et al. 2007; Berger 2007; Kouzarides 2007; 3 
Dekker 2008; Park 2009; Portela and Esteller 2010). Furthermore, it has potential for 4 
identification of epigenetic biomarkers for disease stratification and personalized medicine 5 
(Heyn and Esteller 2012; Dirks et al. 2016). To facilitate such studies, the compatibility of ChIP-6 
seq with low cell-quantity input is highly beneficial to enable the use of relevant biological 7 
specimens, for example mouse early embryonic tissues or human biopsies. With respect to 8 
epigenetic biomarker discovery and screening, it is essential that the ChIP-seq protocol is 9 
sensitive, robust and high-throughput with little hands-on time. For large scale studies and 10 
routine clinical use, it is critical to minimize variation among users and between laboratories. 11 
With the development of PnP-ChIP-seq, we achieved reproducible, robust low-input ChIP 12 
reactions for 24 sample in parallel with only 30 minutes of hands-on time and 4.5 hours 13 
machine-running time. This uniquely allows to perform the full ChIP-seq procedure from 14 
harvesting of the cells up to loading of the ChIP-seq library on a sequencer in a single day. As 15 
the procedure that we pioneered is automated and standardized, PnP-ChIP-seq can conveniently 16 
be applied in non-expert laboratories, provided that these have access to the Fluidigm C1tm or a 17 
similar type of thermodynamic and pneumatic controller, for example the Junotm system. The 18 
fact that such controllers are now commonly available, including at regular core facilities world-19 
wide, makes the PnP-ChIP-seq workflow that we developed widely accessible. As such, PnP-20 
ChIP-seq is unique as compared to previously-engineered automated ChIP-seq workflows (Cao 21 
et al. 2015; Shen et al. 2015; Murphy et al. 2018), which require custom-designed and non-22 
transferable equipment. Furthermore, PnP-ChIP-seq allows to run more samples in parallel (24 23 
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as compared to 4 or less in previous studies), automates a larger part of the workflow and has 1 
lower handling and running times, while we show compatibility with all main hPTMs. Therefore, 2 
the automation and parallelization of the low-input ChIP protocol as reported here paves the way 3 
towards large-scale ChIP-seq profiling of precious sample types. The standardized procedure of 4 
PnP-ChIP-seq will facilitate consistent and reproducible results between laboratories thereby 5 
allowing direct comparisons between ChIP-seq profiles generated in separate laboratories, which 6 
have been challenging thus far (Landt et al. 2012). 7 
 8 
Because traditional ChIP-seq approaches require large amounts of material (Ho et al. 2011; Chen 9 
et al. 2012; Landt et al. 2012), a range of previous studies have worked towards procedures to 10 
downscale the ChIP procedure (Supplemental Fig. S1). These include barcoding and pooling of 11 
multiple samples in the ChIP reaction (Rotem et al. 2015; van Galen et al. 2016; Weiner et al. 12 
2016; Grosselin et al. 2019), the use of carrier material (O'Neill et al. 2006) and application of a 13 
transposase for DNA cleavage and library generation (Schmidl et al. 2015; Ai et al. 2019). 14 
Furthermore, single-cell ChIP-seq approaches have been developed, such as single-cell 15 
CUT&RUN (Hainer et al. 2019; Hainer and Fazzio 2019) or scChIC-Seq (Ku et al. 2019), both 16 
of which depend on antibody-fused MNase, scCUT&Tag (Kaya-Okur et al. 2019) which 17 
depends on an antibody-based tethering of a transposase and single-cell ChIP-seq based on 18 
droplet technology (Rotem et al. 2015; Grosselin et al. 2019). Within the single-cell approaches, 19 
cells are pooled before ChIP. Although single-cell ChIP-seq approaches are very powerful to 20 
dissect cellular heterogeneity, they often require a large amount of starting material, while also 21 
they show very low coverage per cell. In alternative approaches, on-bead ligation of adaptors has 22 
recently been pioneered by lobChIP (Wallerman et al. 2015), SLIM-ChIP (Gutin et al. 2018) and 23 
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iChIP (Lara-Astiaso et al. 2014; Sadeh et al. 2016), during which the DNA is prepared for 1 
sequencing while bound to the beads used in IP, thereby alleviating the necessity for further 2 
sample preparation after ChIP. As ChIP procedures are dependent on immunoprecipitation, all of 3 
these are, in principle, compatible with our PnP-ChIP-seq workflow. The flexibility of our 4 
platform, in terms of (i) the reagents to be loaded; (ii) the flexible circulation schemes of 5 
reagents due to the large number of independent control valves; and (iii) the control over the 6 
temperature, will further facilitate to automate the alternative ChIP approaches using our PnP-7 
ChIP-seq. In view of the better performance of our microfluidic platform as compared to low-8 
input bench ChIP (Fig. 2F) and previously developed microfluidic platforms from which 9 
comparable data was available (Supplemental Fig. S9,S11), the use of the PnP-ChIP-seq might 10 
further increase the sensitivity of these procedures. 11 
 12 
While previous studies that engineered miniaturization of ChIP-seq mainly focused on 13 
H3K4me3 (Cao et al. 2015; Shen et al. 2015; Murphy et al. 2018), we aimed to develop an 14 
automated ChIP-seq workflow for the complete set of six hPTMs which together comprise the 15 
IHEC reference epigenomes (Bujold et al. 2016; Fernandez et al. 2016). By using as few as 16 
15,000 cells as input material and 3,000 cells per ChIP reaction, the PnP-ChIP-seq allows for 17 
profiling of these hPTMs thereby obtaining a comprehensive epigenetic blueprint of cells. In 18 
terms of sensitivity, a comparison between 2i and serum mESCs (Fig. 5) shows that this PnP-19 
ChIP-seq workflow robustly detects differences in promoter (H3K4me3) and enhancer 20 
(H3K27ac and H3K4me1) hPTMs in two closely related cell types. We were able to generate 21 
high-quality H3K4me3 PnP-ChIP-seq profiles by either starting with lower input amounts (7,500 22 
mESCs; Fig. 4A) or loading lower amounts of chromatin per ChIP reaction (equivalent to 100 23 
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mESCs; Fig. 4A). However, such low amounts were not compatible with reproducible high-1 
quality profiles for most of the other hPTMs. Therefore, we advise to use 15,000 cells as optimal 2 
starting amount. 3 
 4 
Low-input cell numbers affect sensitivity of ChIPs (Kidder et al. 2011; Hainer et al. 2019; Ku et 5 
al. 2019), which is clear in the current study from the H3K4me3 average profiles (Supplemental 6 
Fig. S8). However, the use of 3,000 mESCs allowed for the detection of the majority of enriched 7 
sites for H3K4me3, H3K4me1 and H3K36me3. Although profiling of H3K27ac appeared to be 8 
more challenging, similar to previous observations (Murphy et al. 2018), the H3K27ac PnP-9 
ChIP-seq still showed a clear correlation with bulk ChIP-seq (Supplemental Fig. S10A) and 10 
allowed for detection of around half of the total number of enriched sites (Supplemental Fig. 11 
S10B). Antibodies against hPTMs such as H3K4me3 are known for their very low dissociation 12 
constant (Kd)/ high affinity (Hattori et al. 2013), and as such the lower performance for 13 
H3K27ac is likely related to the affinity of the current antibodies against H3K27ac. However, 14 
also other features, including the availability of the H3K27ac epitope in mESCs, might cause the 15 
lower performance of PnP-ChIP-seq for H3K27ac. Nevertheless, given the high correlation 16 
between H3K27ac PnP-ChIP-seq replicates, our platform is highly compatible with H3K27ac 17 
ChIP-seq profiling, albeit at a reduced sensitivity as compared to bulk ChIP-seq. Altogether, we 18 
anticipate that our platform is likely to be compatible with profiling of other hPTMs that we did 19 
not include in this study, depending on the affinity of the hPTM antibody used and the 20 
availability of the hPTM epitope, but likely also dependent on the distribution of the hPTM over 21 
the genome and total levels of the hPTM. Profiling of TFs is known to be generally more delicate 22 
than profiling of hPTMs, requiring large amounts of cells (Park 2009; Furey 2012). TFs are 23 
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generally profiled using crosslinked chromatin to stably capture the binding event of TFs to 1 
chromatin or DNA. In view of the fact that we make use of MNase for shearing of the chromatin, 2 
which is not easily compatible with crosslinked chromatin, profiling of TFs by the use of PnP-3 
ChIP-seq is likely to be challenging. However, it has been shown that ChIP-seq profiling of TFs 4 
on non-crosslinked chromatin by the use of MNase is feasible using a method called ORGANIC 5 
(Kasinathan et al. 2014). Therefore PnP-ChIP-seq may also be useful for analysis of transcription 6 
factors and other non-histone proteins. 7 
 8 
To gain mechanistic insight, we apply PnP-ChIP-seq to study totipotent-like or 2C-like cells that 9 
are present within mESC cell cultures. By comparison of H3K4me3 ChIP-seq of the 2C-like cell 10 
population versus the remainder of the pluripotent (non-2C-like) mESC population, we set out to 11 
investigate whether the 2C-like cell population arises due to stochastic gene activation in mESCs 12 
or due to epigenetic activation of genes by means of deposition of H3K4me3. As we found very 13 
little significant changes in H3K4me3 between 2C-like cells and the remainder of the mESC 14 
population, using either Zscan, MERVL or Hhex promoter activity as marker for 2C-like or 15 
totipotent-like cells, we tentatively conclude that the 2C-like cells likely arise in the mESC 16 
population due to stochastic gene activation. Our findings do not exclude the possibility that the 17 
2C-like state contains unique chromatin features other than related to H3K4me3, for example at 18 
the level of DNA methylation (Macfarlan et al. 2012; Morgani and Brickman 2014; Eckersley-19 
Maslin et al. 2016). Taken together, our results provide a solid rationale for the observations that 20 
mESCs rapidly cycle in and out of the totipotent-like or 2C-like state (Macfarlan et al. 2012; 21 
Morgani and Brickman 2014). The absence of a robust epigenetic program of transcription in the 22 
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transient 2C-like cells likely facilitates the rapid downregulation of the 2C or totipotency genes 1 
after their activation in mESCs. 2 
 3 
Altogether, the universal ChIP device as pioneered in the current study will facilitate 4 
implementation of the labor-intensive and highly sensitive low-input ChIP procedure in regular 5 
laboratories with no expertise in the ChIP procedure. Moreover, given the highly parallelized, 6 
automated workflow, the PnP-ChIP workflow will find its way to specialized epigenetic 7 
laboratories and core facilities enabling large-scale projects and consortia. In view of the 8 
reproducibility and sensitivity, the robustness of the procedure and the low-input requirements, 9 
we anticipate that the PnP-ChIP-seq will be a first step to discovery and screening of hPTM-10 
based biomarkers in the clinic (Martens et al. 2010; Ross-Innes et al. 2012; Saeed et al. 2012; 11 
Jansen et al. 2013; Stelloo et al. 2015; Cejas et al. 2016; Dirks et al. 2016). Whether in a research 12 
setting or in the clinic, implementation of PnP-ChIP-seq will benefit from the fact that our 13 
workflow is based on a commercially available microfluidic platform. In addition, we foresee 14 
that the concept presented here can also be easily adapted to other programmable microfluidic 15 
platforms with a similar design, namely nanoliter-sized affinity purification columns targeting 16 
chromatin-associated proteins with pressure-driven laminar flow of buffers and lysates. 17 
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Methods 1 
Cell culture and Fluorescence-Activated Cell Sorting (FACS) 2 
E14 mESCs (129/Ola background; also referred to as “serum” mESCs) and the reporter mESCs 3 
were maintained without feeders in Dulbecco’s Modified Eagle Medium (Thermo Fisher 4 
Scientific) containing 15% Fetal Bovine Serum (Cell Signaling Technologies), 1,000U/mL 5 
Leukemia Inhibitory Factor (LIF; Millipore), 5µM beta-mercaptoethanol (Sigma-Aldrich) and 6 
1mM sodium pyruvate (Thermo Fisher Scientific). The so-called “2i” mESCs were ES cells were 7 
cultured without feeders in the presence of 1,000U/mL LIF in serum-free N2B27 supplemented 8 
with MEK inhibitor PD0325901 (1 mM) and GSK3 inhibitor CH99021 (3 mM), together known 9 
as 2i. Generation of Hhex::Venus reporter mESCs (Morgani et al. 2013), 10 
Zscan4c::Emerald(Em)-GFP reporter mESCs (Eckersley-Maslin et al. 2016) and MuERV-11 
L(MERVL)::tdTomato reporter mESCs (Eckersley-Maslin et al. 2016) have been described 12 
before. Further details about FACS are described in the Supplemental Methods. 13 
 14 
Chromatin Immunoprecipitation (ChIP), library preparation for ChIP-seq and (RT-15 
)qPCR 16 
Conventional cross-linked ChIP and library preparation for ChIP-seq was performed as 17 
described previously (van Mierlo et al. 2019), further details are present in the Supplemental 18 
Methods. (RT-)qPCR was performed according to standard protocols, as described in the 19 
Supplemental Methods. 20 
 21 
Low-input microfluidic ChIP 22 
 28
Crosslinked chromatin was prepared from a cell suspension according to the conventional 1 
protocol as described above, with volumes downscaled to match the concentrations of cells used. 2 
For low-volume sonication, we used the Diagenode One sonication device according to the 3 
instructions of the manufacturer. For native ChIP-seq, non-crosslinked chromatin of 7,500 or 4 
15,000 mESCs were digested using MNase (NEB M0247) for 5-15 minutes at 20°C, after which 5 
the quality of the digestion was checked on a Bioanalyzer (Agilent). After digestion, the 6 
chromatin was diluted two-fold in 60mM Tris pH8.0, 300mM NaCl, 1µg/µL antibody and 2x 7 
protease inhibitor cocktail (freshly prepared). For microfluidic ChIP, final volumes were kept 8 
below 20µL to ensure short loading times across the pre-packed antibody affinity bead column. 9 
Both crosslinked as well as native chromatin was snap frozen in liquid nitrogen and stored at -10 
80°C for later use. The microfluidic ChIP operation protocol is outlined in the results section and 11 
in the Supplemental Figures. The various buffers used are: control valve fluids (0.05% Tween 12 
20), harvesting buffer (30mM Tris pH 8.5), Equilibration buffer (2mM EDTA, 20mM Tris 13 
pH8.0, 1% Triton X-100, 0.1% SDS, 150mM NaCl), High Salt wash buffer (2mM EDTA, 14 
20mM Tris pH8.0, 1% Triton X-100, 0.1% SDS, 500mM NaCl), DNA extraction buffer 15 
(150mM NaCl, 30mM Tris pH 8.0, 0.1µg/µL Proteinase K (Sigma-Aldrich)) and DNA elution 16 
buffer (10mM Tris pH 8.5). Both wash buffers included addition of freshly dissolved EDTA-free 17 
complete proteins inhibitors (Roche®). Microfluidic ChIP-seq libraries were constructed using 18 
Rubicon ThruPLEX library preparation kits according to the protocol of the manufacturer using 19 
10 cycles of amplification. Ampure XP beads were used to select for DNA fragments of 300 bp 20 
in size (120 bp adaptor and 180 bp insert). Quality control for size and concentration was 21 
performed using the Agilent Bioanalyzer. The antibodies used for ChIP: H3K4me3 (Diagenode 22 
C1540003), H3K4me1 (Diagenode C1540194), H3K27ac (Diagenode C15410196; lot #A1723-23 
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0041d), H3K36me3 (Diagenode pAb-192-050), H3K27me3 (Millipore 04-779) and H3K9me3 1 
(C15410193, pAb-193-050; lot #A1671-001P). 2 
 3 
Sequencing and data analysis 4 
Samples were sequenced 42 bp paired-end using Illumina NextSeq 500. Bowtie 2 (version 2.0.2) 5 
(Langmead and Salzberg 2012) was used to map using the mm9 genome. We used mm9 to allow 6 
easier comparisons with previous data, but the use of mm10 would not affect our conclusions as 7 
the reference genomes mm9 and mm10 are very similar. Unmapped, duplicate and low quality 8 
(mapq<15) reads were removed. SICER was used for peak calling (window size 200, gap size 9 
200 for H3K4me3; window size 200, gap size 600 for H3K36me3, H3K4me1 & H3K27ac, E-10 
value 0.1). Empirically determined artificially enriched signal was excluded (ENCODE mm9 11 
blacklist (The ENCODE Project Consortium 2012; Amemiya et al. 2019)). BEDTools v2.20.1 12 
and pybedtools were used for peak call intersections and tag counting on peaks or promoter 13 
regions. DESeq2 (Love et al. 2014) was used for calling of differential PnP-ChIP-seq loci (FDR-14 
adjusted p-value < 0.05 as cut-off for calling significant difference) and PCA analysis. For direct 15 
comparison of loci between marker-positive (2C-like cells) versus marker-negative mESCs for 16 
either HHEX, MERVL or ZSCAN4C, we used a cutoff >10 read normalized tags per H3K4me3 17 
promoter. Heatmaps and average profiles were created using ngsplot v2.61 (Shen et al. 2014). 18 
GO and KEGG analysis was performed using DAVID v6.8 (Dennis et al. 2003). In the 2i and 19 
serum mESC analysis, we linked the H3K4me3 peaks to the closest gene. ChIP-seq Repeat 20 
analysis was performed as described in the Supplemental Methods. 21 
 22 
Data access 23 
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All raw and processed sequencing data generated in this study have been submitted to the NCBI 1 
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Figure Legends 1 
 2 
Figure 1. Overview of the microfluidic chip design for automated microfluidic chromatin 3 
immunoprecipitation. (A) Workflow of automated microfluidic ChIP-seq. (B) Overview of the 4 
interface plate. At the sides are the inlets, while the PDMS microfluidic chip containing the 5 
micro-reactors is located in the center. (C) Architecture of PDMS microfluidic chip, also referred 6 
to as Integrated Fluidic Circuit (IFC). The bead inlet is in green, the antibody and chromatin inlet 7 
in orange, the channel in which the bead column is constructed in blue, the inlet for various 8 
buffers needed in the workflow in pink, the waste and harvest outlet in yellow. The control 9 
valves are colored red. (D) Phase contrast image of six out of twenty-four parallel microfluidic 10 
bead columns on every chip. 11 
 12 
Figure 2. Optimization of parameters for the automated microfluidic ChIP protocol. ChIP-qPCR 13 
are depicted on a positive (Actb) and a negative locus, with H3K4me3 recoveries plotted with +/- 14 
standard error of the mean. (A) Recoveries using various types of frit layer composition that 15 
allows packing of antibody binding beads in the microfluidic reactors. (B) Recoveries using 16 
various column sizes (Supplemental Fig. S4A) built using different amounts of antibody binding 17 
beads. (C) Recoveries of various types of beads used to construct the antibody binding column. 18 
(D) Recoveries using varying chromatin loading pressures. (E) Final recoveries with optimized 19 
parameters as compared to initial testing. (F) Recoveries of conventional versus low-input 20 
automated microfluidic ChIP-qPCR, showing high yields and reproducibility of microfluidic 21 
ChIP as compared to conventional chip. 22 
 23 
 32
Figure 3. PnP-ChIP-seq using small quantites of bulk-sonicated crosslinked chromatin. (A) 1 
Gene-centered genome browser view for PnP-ChIP-seq of H3K4me3, H3K4me1, H3K27ac and 2 
H3K36me3. (B) Heatmap of merged peak set for various starting amount of sonicated chromatin 3 
for PnP-ChIP-seq of H3K4me3, H3K4me1, H3K27ac and H3K36me3. “r” = replicate. (C) 4 
Cross-correlations of PnP-ChIP-seq using tag counts of merged peak set. (D) Overlap between 5 
de novo peak calls of PnP-ChIP-seq and bulk ChIP-seq. (E-F) Overlap between de novo peak 6 
calls of PnP-ChIP-seq. 7 
 8 
Figure 4. PnP-ChIP-seq using small cell quantities of mESCs by the use of MNase. (A) Gene-9 
centered genome browser view for PnP-ChIP-seq of H3K4me3, H3K4me1, H3K27ac and 10 
H3K36me3. Profiles labelled with * were generated from a starting amount of 7,500 mESCs, 11 
otherwise 15,000 mESCs. (B) Overlap between de novo peak calls of PnP-ChIP-seq and bulk 12 
ChIP-seq. (C) Heatmap of merged peak set for various starting amount of sonicated chromatin 13 
for PnP-ChIP-seq of H3K4me3, H3K4me1, H3K27ac and H3K36me3. (D) Cross-correlations of 14 
PnP-ChIP-seq using tag counts of merged peak set. 15 
 16 
Figure 5. PnP-ChIP-seq allows to detect significant differences between 2i and serum mESCs. 17 
(A) PCA on peaks of H3K4me3, H3K27ac and H3K4me1 PnP-ChIP-seq in 2i and serum 18 
mESCs. “rep” = replicate. (B) Genome browser views for PnP-ChIP-seq of loci showing a 19 
significant difference in H3K4me3, H3K27ac or H3K4me1 between 2i and serum mESCs 20 
(boxed). “H3*peaks_all” = all peaks of a hPTM detected in 2i and serum mESCs. 21 
“H3*peaks_sig” = all peaks of a hPTM that are significantly increased in either 2i or serum 22 
 33
mESCs. (C) GO and KEGG (Kyoto encyclopedia of genes and genomes) pathway analysis of 1 
genes associated with differential H3K4me3 between 2i and serum mESCs. 2 
 3 
Figure 6. Epigenomic analysis of various totipotent-like cells or “2 cell-stage like” (2C-like) 4 
mESC subpopulations. (A) Experimental outline for sorting and analysis of 2C-like mESC 5 
subpopulations. (B) RT-qPCR on mESC subpopulations to validate successful FACS sorting. 6 
(C-D) A genome browser view depicting a broad genomic region (4MB) (C) and a zoom in (D) 7 
of the H3K4me3 profiles generated for the 2C-like mESC subpopulations and their controls. (E) 8 
PCA on the promoter-associated H3K4me3 signals of the various populations of cells. “+” = 9 
positive for marker, “-” = negative for marker. (F) Correlation of H3K4me3 signal in promoters 10 
between HHEX, MERVL or ZSCAN4C marker-positive mESCs (2C-like mESC 11 
subpopulations) and marker-negative mESCs; no differential sites were detected (FDR-adjusted 12 
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DAVID GO terms Biological Processes
Term Count % of all in 
category
P-Value
Protein metabolic process 894 35.2 2.90E-34
Cell cycle 350 13.8 3.00E-37
Cellular nitrogen compound metabolic process 996 39.2 6.50E-27
regulaƟon of cellular component organizaƟon 429 16.9 1.40E-16
Phosphorus metabolic process 462 18.2 9.60E-10
Response to oxidaƟve stress 80 3.1 5.00E-04
Stem cell populaƟon maintenance 37 1.5 5.90E-04
Blastocyst development 22 0.9 4.80E-02
KEGG pathway
Term Count % of all in 
category
P-Value
Protein processing in endoplasmic reƟculum 53 2.1 4.40E-08
Cell cycle 40 1.6 2.70E-06
Signaling pathways regulaƟng pluripotency of stem cells 34 1.3 1.80E-03
Wnt signaling pathway 32 1.3 9.80E-03
Long-term potenƟaƟon 17 0.7 4.30E-02
H3K4me3 higher serum
DAVID GO terms Biological Processes
Term Count % of all in 
category
P-Value
Cellular macromolecule metabolic process 288 50.5 1.50E-11
RegulaƟon of biosyntheƟc process 159 27.9 4.50E-06
Organelle organizaƟon 125 21.9 8.60E-03
Tube development 35 6.1 9.90E-03
Developmental growth 35 6.1 1.20E-02
Stem cell populaƟon maintenance 13 2.3 1.40E-02
Heart development 29 5.1 4.50E-02
H3K4me3 higher 2i
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Response to oxidaƟve stress 80 3.1 5.00E-04
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Blastocyst development 22 0.9 4.80E-02
KEGG pathway
Term Count % of all in 
category
P-Value
Protein processing in endoplasmic reƟculum 53 2.1 4.40E-08
Cell cycle 40 1.6 2.70E-06
Signaling pathways regulaƟng pluripotency of stem cells 34 1.3 1.80E-03
Wnt signaling pathway 32 1.3 9.80E-03
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Cellular macromolecule metabolic process 288 50.5 1.50E-11
RegulaƟon of biosyntheƟc process 159 27.9 4.50E-06
Organelle organizaƟon 125 21.9 8.60E-03
Tube development 35 6.1 9.90E-03
Developmental growth 35 6.1 1.20E-02
Stem cell populaƟon maintenance 13 2.3 1.40E-02
Heart development 29 5.1 4.50E-02
ChIP
RNA
Sort 
populations
ChIP
RNA
ChIP
RNA
Sort 
populations
ChIP
RNA
ChIP
RNA
mm9Scale
Chr17:
Scale
Chr3:
Scale
Chr6:
Pou5f1 Sox2 Nanog
